Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarr, Paul M-
dc.contributor.authorTedeschi, Alessandra-
dc.contributor.authorWierda, William G-
dc.contributor.authorAllan, John N-
dc.contributor.authorGhia, Paolo-
dc.contributor.authorVallisa, Daniele-
dc.contributor.authorJacobs, Ryan-
dc.contributor.authorO'Brien, Susan-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorWalker, Patricia-
dc.contributor.authorZhou, Cathy-
dc.contributor.authorNinomoto, Joi-
dc.contributor.authorKrigsfeld, Gabriel-
dc.contributor.authorTam, Constantine S-
dc.identifier.citationClinical Cancer Research : an Official Journal of the American Association for Cancer Research 2022; 28(20): 4385-4391en
dc.description.abstractThe phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohorts. In both cohorts, patients initially received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). In the total population (N = 323), the following decreases from baseline to after ibrutinib lead-in were observed: percentage of patients with a lymph node diameter ≥5 cm decreased from 31% to 4%, with absolute lymphocyte count ≥25 × 109/L from 76% to 65%, with high tumor burden category for TLS risk from 23% to 2%, and with an indication for hospitalization (high TLS risk, or medium TLS risk and creatinine clearance <80 mL/minute) from 43% to 18%. Laboratory TLS per Howard criteria occurred in one patient; no clinical TLS was observed. Three cycles of ibrutinib lead-in before venetoclax initiation provides effective tumor debulking, decreases the TLS risk category and reduces the need for hospitalization for intensive monitoring for TLS.en
dc.titleEffective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Cancer Research : an Official Journal of the American Association for Cancer Researchen
dc.identifier.affiliationPeter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationPeninsula Health and Peninsula Private Hospital, Frankston, Victoria, Australiaen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York..en
dc.identifier.affiliationASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.en
dc.identifier.affiliationDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas..en
dc.identifier.affiliationWeill Cornell Medicine, New York, New York.en
dc.identifier.affiliationDivision of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy..en
dc.identifier.affiliationOspedale Guglielmo da Saliceto, Piacenza, Italy.en
dc.identifier.affiliationLevine Cancer Institute, Charlotte, North Carolina.en
dc.identifier.affiliationUC Irvine, Chao Family Comprehensive Cancer Center, Irvine, California.en
dc.identifier.affiliationPharmacyclics LLC, an AbbVie Company, South San Francisco, California.en
dc.identifier.pubmedid35939599-, Andrew P
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en- Newton-John Cancer Wellness and Research Centre- Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 21, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.